

Instructions for Authors 2018

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works in the field of cancer research that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to peer-review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. All manuscripts submitted to AR are urgently treated with absolute confidence, with access restricted to the Managing Editor, the journal's secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH-funded research retain the right to provide a copy of the published manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double – spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding 4 printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "review", "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) *Abstract* not exceeding 150 words, organized according to the following headings: Background/Aim – Materials and Methods/Patients and Methods – Results – Conclusion; (c) *Introduction*; (d) *Materials and Methods/Patients and Methods*; (e) *Results*; (f) *Discussion*; (g) *Acknowledgements*; (h) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures should appear at the end of the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Pages that include color figures are subject to color charges..

Tables. All tables should appear at the end of the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

References. Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.)). New York, Plenum Publ Corp., pp 113-136, 1973.

Nomenclature and Abbreviations. Nomenclature should follow that given in “Chemical Abstracts”, “Index Medicus”, “Merck Index”, “IUPAC -IUB”, “Bergey’s Manual of Determinative Bacteriology”, The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by ‘NCT’). Please note that there is no space between the prefix ‘NCT’ and the number. Example: NCT00001789.

Ethical Policies and Standards. ANTICANCER RESEARCH agrees with and follows the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the “Minimum Information About Microarray Experiments (MIAME) standard”. Specific guidelines are provided at the “Microarray Gene Expression Data Society” (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human fetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions for Authors regarding the format of your manuscript and references. Manuscripts must be submitted only through our online submission system at: <http://www.iar-submissions.com/login.html>. In case a submission is incomplete, the corresponding Author will be notified accordingly. Questions regarding difficulties in using the online submission system should be addressed to: email: journals@iar-anticancer.org

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Authors of online open access articles are entitled to a complimentary online subscription to Anticancer Research for the current year and all previous digital content since 2004. Requests should be addressed to the Editorial Office. Galley proofs should be returned corrected to the Editorial Office by email within two days.

Specific information and additional instructions for Authors

1. Anticancer Research (AR) closely follows the new developments in all fields of experimental and clinical cancer research by (a) inviting reviews on topics of immediate importance and substantial progress in the last three years, and (b) providing the highest priority for rapid publication to manuscripts presenting original results judged to be of exceptional value. Theoretical papers will only be considered and accepted if they bear a significant impact or formulate existing knowledge for the benefit of research progress.
2. Anticancer Research will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees.
3. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail or during electronic submission.
4. Each manuscript submitted to AR is sent for review in confidence to two suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to AR, are treated in confidence, without access to any person other than the Managing Editor, the journal’s secretary, the reviewers and the printers.

5. All accepted manuscripts are peer-reviewed and carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author's writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.
6. Authors should pay attention to the following points when writing an article for AR:
 - The Instructions to Authors must be followed in every detail.
 - The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
 - The presentation of results should be simple and straightforward in style. Results and discussion should not be combined into one section, unless the paper is short.
 - Results given in figures should not be repeated in tables.
 - Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
 - Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
 - Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
 - Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
 - Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by... authors, year).
 - The References section should provide as complete a coverage of the literature as possible including all the relevant works published up to the time of submission.
 - By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.
7. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.
8. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).
9. Articles submitted to AR may be rejected without review if:
 - they do not fall within the journal's policy.
 - they do not follow the instructions for authors.
 - language is unclear.
 - results are not sufficient to support a final conclusion.
 - results are not objectively based on valid experiments.
 - they repeat results already published by the same or other authors before the submission to AR.
 - plagiarism is detected by plagiarism screening services.

(Rejection rate (2016): 66%).
10. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.
11. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to journals@iia-anticancer.org
12. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.
13. Authors, Editors and Publishers of books are welcome to submit their books for immediate review in AR. There is no fee for this service. (This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of AR).

Copyright© 2018 - International Institute of Anticancer Research (G.J. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

Contents

Reviews

Pathophysiological Mechanisms of Renal Fibrosis: A Review of Animal Models and Therapeutic Strategies. A. NOGUEIRA, M.J. PIRES, P.A. OLIVEIRA (Vila Real, Braga, Portugal) 1

Prevalence of EGFR Tyrosine Kinase Domain Mutations in Head and Neck Squamous Cell Carcinoma: Cohort Study and Systematic Review. C. PERISANIDIS (Vienna, Austria) 23

Clinical Factors Associated with Treatment Outcomes Following Whole-brain Irradiation in Patients with Prostate Cancer. L. DZIGGEL, S.E. SCHILD, T. VENINGA, A. BAJROVIC, D. RADES (Lübeck/Hamburg, Germany; Scottsdale, AZ, USA; Tilburg, the Netherlands) 35

Experimental Studies

Effectiveness of Analogs of the GS-Nitroside, JP4-039, as Total Body Irradiation Mitigators. M.W. EPPERLY, J.R. SACHER, T. HRANIZ, X. ZHANG, P. WIPP, M. LIANG, R. FISHER, S. LI, H. WANG, J.S. GREENBERGER (Pittsburgh, PA, USA) 39

Active and Passive Immunization Against *Staphylococcus aureus* Periprosthetic Osteomyelitis in Rats. N.H.SÖL, N.V. JENSEN, A.L. JENSEN, J. KOCH, S.S. POULSEN, G.B. PIER, H.K. JOHANSEN (Hallerup, Copenhagen; Hørsholm, Denmark; Boston, MA, USA) 45

Gene Expression Analysis of Cultured Rat-Endothelial Cells after Nd:YAG Laser Irradiation by Affymetrix GeneChip Array. Y. MASUDA, S. YOKOSE, H. SAKAGAMI (Saitama, Japan) 51

Wound Healing Delay in the ZSD Rat. M.A. SUCKOW, T.A. GOBBETT, R.G. PETERSON (St. Paul, MN; Indianapolis, IN, USA) 55

Pulsed Electromagnetic Field Stimulation Promotes Anti-cell Proliferative Activity in Doxorubicin-treated Mouse Osteosarcoma Cells. Y. MURAMATSU, T. MATSUI, M. DEBE, K. SATO (Aichi, Japan) 61

Content continued on the back cover

ISSN (online): 1791-7549

General Policy

- **IN VIVO** is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of human physiology, pathology and disease management. A special focus of the journal is the publication of works on: (a) Experimental development and application of new diagnostic procedures; (b) Pharmacological and toxicological evaluation of new drugs and drug combinations; (c) Clinical trials; (d) Development and characterization of models of biomedical research.
- The principal aim of **IN VIVO** is to provide prompt online publication for accepted articles, generally within 1-2 months from final acceptance.
- **Editorial Office:** International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389.

U.S. Branch: Anticancer Research Inc., USA, 111 Bay Avenue, Highlands, NJ, USA.

- **E-mail:** journals@iia-anticancer.org; IIA WEBSITES: www.iia-anticancer.org and www.iiajournals.org

- **International Journal of Experimental and Clinical Pathophysiology and Drug Research**
- **Published bimonthly by the International Institute of Anticancer Research**
- **Available online only and open access with Stanford University HighWire Press**

● Selection of Recent Articles

Challenges in the Analysis of Outcomes for Surgical Compared to Radiotherapy Treatment of Prostate Cancer. S.M. GLASER, R. KALASH, D.R. BONGIORNI, M.S. ROBERTS, G.K. BALASUBRAMANI, B.L. JACOBS, S. BERIWAL, D.E. HERON, J.S. GREENBERGER (Duarte, CA; Pittsburgh, PA, USA)

Morphological Distinction of Histiocytic Sarcoma from Other Tumor Types in Bernese Mountain Dogs and Flatcoated Retrievers. S.A. ERICH, F. CONSTANTINO-CASAS, J.M. DOBSON, E. TESKE (Utrecht, The Netherlands; Cambridge, UK)

Tissue-directed Implantation Using Ultrasound Visualization for Development of Biologically Relevant Metastatic Tumor Xenografts. R.A. VAN NOORD, T. THOMAS, M. KROOK, S. CHUKKAPALLI, M.J. HOENERHOFF, J.R. DILLMAN, E.R. LAWLOR, V.P. OPIPARI, E.A. NEWMAN (Ann Arbor, MI, USA)

Re-evaluation of Culture Condition of PC12 and SH-SY5Y Cells Based on Growth Rate and Amino Acid Consumption. H. SAKAGAMI, R. SUZUKI, Y. SHIRATAKI, S. IWAMA, M. NAKAGAWA, H. SUZUKI, K. TANAKA, N. TAMURA, H. TAKESHIMA (Sakado, Japan)

Clinical Impact of Rest Dual-Energy Computed Tomography Myocardial Perfusion in Patients with Coronary Artery Disease. S. BAUMANN, *et al.* (Mannheim, Germany)

Effects of 2,3-Bis(4-hydroxyphenyl)-propionitrile on Induction of Polyovular Follicles in the Mouse Ovary. T. SATO, H. KIM, H. KAKUTA, T. IGUCHI (Yokohama, Japan)

Cell-cycle Checkpoints and Aneuploidy on the Path to Cancer. E.S. WENZEL, A.T.K. SINGH (Kenosha, WI, USA)

The Association of MMP-8 Genotypes with Pterygium. P.-S. HU, W.-S. CHANG, A.-K. CHOU, N.-Y. HSIA, Y.-W. HUNG, C.-W. LIN, C.-W. WU, C.-Y. HUANG, M.-F. WU, C.-H. LIAO, C.-W. TSAI, D.-T. BAU, C.-L. GONG (Changhua; Taichung; Taoyuan, Taiwan, ROC)

Profiling Neutrophil-to-Lymphocyte Ratio Changes in Response to Nucleoside Analog Therapy for Chronic Hepatitis B Infection. M. MARALLAG, A. PATEL, M. CHOI, M.N. WONG, A.B. SEETHARAM (Phoenix; Tempe, AZ, USA)

Comparison of the Grip Strength Using the Martin-Vigormeter and the JAMAR-Dynamometer: Establishment of Normal Values. S. NEUMANN, S. KWISDA, C. KRETTEK, R. GAULKE (Hannover; Hamburg, Germany; Zurich, Switzerland)

Role for Neutrophil Extracellular Traps (NETs) and Platelet Aggregation in Early Sepsis-induced Hepatic Dysfunction. K. SAKURAI, T. MIYASHITA, *et al.* (Ishikawa, Japan; Baltimore, MD, USA)

Netrin-4 Promotes Differentiation and Migration of Osteoblasts. Y. ENOKI, T. SATO, S. KOKABU, N. HAYASHI, T. IWATA, M. YAMATO, M. USUI, M. MATSUMOTO, T. TOMODA, W. ARIYOSHI, T. NISHIHARA, T. YODA (Saitama; Fukuoka; Tokyo, Japan)

Early PET-CT After Stereotactic Radiotherapy for Stage I Non-small-cell Lung Carcinoma Is Predictive of Local Control. M. TYRAN, N. CHARRIER, J. DARREON, A. MADROSZYK, A. TALLET, N. SALEM (Marseille, France)

Plasma Electrolytic Oxidation of Titanium Implant Surfaces: Microgroove-Structures Improve Cellular Adhesion and Viability. P. HARTJEN, A. HOFFMANN, A. HENNINGSSEN, M. BARBECK, A. KOPP, L. KLUWE, C. PRECHT, O. QUATELA, R. GAUDIN, M. HEILAND, R.E. FRIEDRICH, D. GRUBEANU, R. SMEETS, O. JUNG (Hamburg-Eppendorf; Idstein; Berlin; Aachen, Germany)

Tumor Hypoxia Detected by ¹⁸ F-fluoromisonidazole Positron Emission Tomography (FMISO PET) as a Prognostic Indicator of Radiotherapy (RT). I. TACHIBANA, Y. NISHIMURA, K. HANAOKA, M. INADA, K. FUKUDA, H. TATEBE, K. ISHIKAWA, K. NAKAMATSU, S. KANAMORI, M. HOSONO (Osakasayama, Japan)	1775
Skin Rash Can Be a Useful Marker for Afatinib Efficacy. S. NASU, H. SUZUKI, T. SHIROYAMA, A. TANAKA, K. IWATA, N. RYOTA, Y. UEDA, S. TAKATA, K. MASUHIRO, S. MORITA, N. MORISHITA, N. OKAMOTO, T. HIRASHIMA (Osaka, Japan)	1783
Defunctioning Ileostomy Is a Key Risk Factor for Small Bowel Obstruction After Colorectal Cancer Resection. K. ETO, M. KOSUGE, M. OHKUMA, R. NOAKI, K. NEKI, D. ITO, H. SUGANO, Y. TAKEDA, K. YANAGA (Tokyo, Japan)	1789
Spatiotemporal Analysis of Breast Cancer Incidence: A Study in Southern Portugal Between 2005 and 2012. I. GOMES, A. MIRANDA, C. NUNES (Lisbon, Portugal)	1797
Clinical Value of Serum p53 Antibody in the Diagnosis and Prognosis of Esophageal Squamous Cell Carcinoma. M. KUNIZAKI, K. HAMASAKI, K. WAKATA, S. TOBINAGA, Y. SUMIDA, S. HIDAKA, T. YASUTAKE, T. MIYAZAKI, K. MATSUMOTO, T. YAMASAKI, T. SAWAI, R. HAMAMOTO, A. NANASHIMA, T. NAGAYASU (Nagasaki; Tokyo, Japan)	1807
Outcome of Trimodal Therapy in Elderly Patients with Esophageal Cancer: Prognostic Value of the Charlson Comorbidity Index. D. BERNARDI, E. ASTI, A. AIOLFI, G. BONITTA, A. LUPORINI, L. BONAVINA (Milan, Italy)	1815
High Frequency of Spread Through Air Spaces in Resected Small Cell Lung Cancer. G. TOYOKAWA, Y. YAMADA, T. TAGAWA, F. KINOSHITA, Y. KOZUMA, T. MATSUBARA, N. HARATAKE, S. TAKAMORI, T. AKAMINE, F. HIRAI, Y. ODA, Y. MAEHARA (Fukuoka, Japan)	1821
ABSTRACTS OF THE 5TH INTERNATIONAL CONFERENCE ON ADVANCES IN HEMATOLOGY AND ONCOLOGY (ICAHO2017) 12-13 August, 2017 (Coeur d'Alene, ID, USA)	1827

Evaluation of Optimal Lymph Node Dissection in Remnant Gastric Cancer Based on Initial Distal Gastrectomy. K. IGUCHI, C. KUNISAKI, S. SATO, Y. TANAKA, H. MIYAMOTO, T. KOSAKA, H. AKIYAMA, I. ENDO, Y. RINO, M. MASUDA (<i>Yokohama, Japan</i>)	1677
Prognostic Significance of High EphA1-4 Expression Levels in Locally Advanced Gastric Cancer. M. INOKUCHI, M. NAKAGAWA, N. BAOGOK, Y. TAKAGI, T. TANIOKA, K. GOKITA, K. OKUNO, K. KOJIMA (<i>Tokyo, Japan</i>)	1685
Rates, Sites and Times of Recurrence and Clinical Outcome of Endometrial Cancer Patients with Histologically-positive Nodes: An Italian Two-center Retrospective Study. A. GADDUCCI, M.E. GUERRIERI, S. COSIO, M.G. FABRINI, C. LALISCIA, D. ATTIANESE, A. ROSSI, A. FERRERO (<i>Pisa; Turin, Italy</i>)	1695
Contribution of Patient-reported Symptoms Before Palliative Radiotherapy to Development of Multivariable Prognostic Models. C. NIEDER, T.A. KÄMPE (<i>Bodø; Tromsø, Norway</i>)	1705
Case Report: CEA Elevation Can Be a Marker of Increased Inflammation During Treatment with Oxaliplatin. D. KERR, D. LABER, N. VISWESHWAR, M. JAGLAL (<i>Tampa, FL, USA</i>)	1711
Safety of Simultaneous Bilateral Pulmonary Resection for Metastatic Lung Tumors. T. MATSUBARA, G. TOYOKAWA, F. KINOSHITA, N. HARATAKE, Y. KOZUMA, T. AKAMINE, S. TAKAMORI, F. HIRAI, T. TAGAWA, T. OKAMOTO, Y. MAEHARA (<i>Fukuoka, Japan</i>)	1715
Laparoscopy-assisted Distal Gastrectomy for Gastric Cancer in Elderly Patients: Surgical Outcomes and Prognosis. K. ARATANI, S. SAKURAMOTO, M. CHUMAN, M. KASUYA, M. WAKATA, Y. MIYAWAKI, H. GUNJI, H. SATO, K. OKAMOTO, S. YAMAGUCHI, E. OTSUJI, I. KOYAMA (<i>Hidaka; Kyoto, Japan</i>)	1721
Barriers to Organized Mammography Screening Programs in Hungary: A Questionnaire-based Study of 3,313 Women. M. ÚJHELYI, D. PUKANCSIK, P. KELEMEN, E. KOVÁCS, I. KENESSEY, M. BAK, M. KÁSLER, T. KOVÁCS, Z. MÁTRAI (<i>Budapest, Hungary; London, UK</i>)	1727
Ki-67 and Survivin as Predictive Factors for Rectal Cancer Treated with Preoperative Chemoradiotherapy. K. YOSHIKAWA, M. SHIMADA, J. HIGASHIJIMA, T. NAKAO, M. NISHI, C. TAKASU, H. KASHIHARA, S. ETO, Y. BANDO (<i>Tokushima, Japan</i>)	1735
A Feasibility Study of Capecitabine and Oxaliplatin for Patients with Stage II/III Colon Cancer –ACTOR Study. M. SUENAGA, T. AKIYOSHI, E. SHINOZAKI, Y. FUJIMOTO, S. MATSUSAKA, T. KONISHI, S. NAGAYAMA, Y. FUKUNAGA, K. KAWAKAMI, T. YOKOKAWA, T. SUGISAKI, M. UENO, T. YAMAGUCHI (<i>Tokyo, Japan</i>)	1741
Self-expandable Metallic Stents Contribute to Reducing Perioperative Complications in Colorectal Cancer Patients with Acute Obstruction. H. FURUKE, S. KOMATSU, J. IKEDA, S. TANAKA, T. KUMANO, K.-I. IMURA, K. SHIMOMURA, F. TANIGUCHI, Y. UESHIMA, K.-I. TAKASHINA, C.J. LEE, E. DEGUCHI, E. IKEDA, E. OTSUJI, Y. SHIOAKI (<i>Kyoto, Japan</i>)	1749
The Modified Glasgow Prognostic Score in Patients with Gemcitabine-refractory Biliary Tract Cancer. N. OKANO, A. KASUGA, K. KAWAI, Y. YAMAUCHI, T. KOBAYASHI, D. NARUGE, F. NAGASHIMA, J. FURUSE (<i>Tokyo, Japan</i>)	1755
Preoperative Staging of Pelvic Lymph Nodes in Prostate Cancer Patients via Endorectal Magnetic Resonance Imaging. V. ZUGOR, M. VON BRANDENSTEIN, I. AKBAROV, D. PORRES, R. KÜHN, A.P. LABANARIS (<i>Cologne; Nuremberg, Germany; Thessaloniki, Greece</i>)	1763
Clinicopathological Characteristics of High-grade Squamous Intraepithelial Lesions Involving Condyloma Acuminatum. K. NA, J.-Y. SUNG, H.-S. KIM (<i>Seoul, Republic of Korea</i>)	1767

Is Mistletoe Treatment Beneficial in Invasive Breast Cancer? A New Approach to an Unresolved Problem. P. FRITZ, J. DIPPON, S. MÜLLER, S. GOLETZ, C. TRAUTMANN, X. PAPPAS, G. OTT, H. BRAUCH, M. SCHWAB, S. WINTER, T. MÜRDTER, F. BRINKMANN, S. FAISST, S. RÖSSLE, A. GERTEIS, G. FRIEDEL (<i>Stuttgart; Winnenden, Germany</i>)	1585
A Case of 15-Year Recurrence-free Survival After Microwave Coagulation Therapy for Liver Metastasis from Gastric Cancer. K. KINOSHITA, T. BEPPU, T. MIYATA, K. KURAMOTO, Y. YOSHIDA, N. UMESAKI, Y. KITANO, S. NAKAGAWA, H. OKABE, H. NITTA, K. IMAI, H. HAYASHI, Y.-I. YAMASHITA, H. KOMORI, K. HORINO, A. MISUMI, H. BABA (<i>Kumamoto, Japan</i>)	1595
Clinical Burden of Modified Glasgow Prognostic Scale in Colorectal Cancer. Y. OKUGAWA, Y. SHIRAI, Y. TOIYAMA, S. SAIGUSA, A. HISHIDA, T. YOKOE, K. TANAKA, M. TANAKA, H. YASUDA, H. FUJIKAWA, J. HIRO, M. KOBAYASHI, T. ARAKI, Y. INOUE, D.C. MCMILLAN, M. KUSUNOKI, C. MIKI (<i>Mie; Nagoya, Japan; Glasgow, UK</i>)	1599
A New Scoring-system for Estimating Overall Survival After Radiotherapy of Recurrent Head and Neck Cancers. D. RADES, D. SEIDL, S. JANSSEN, S.G. HAKIM, B. WOLLENBERG, T. BARTSCHT, S.E. SCHILD (<i>Lübeck; Hannover, Germany; Scottsdale, AZ, USA</i>).....	1611
An Exploratory Study of Radiation Dermatitis in Breast Cancer Patients. E. ALEXOPOULOU, T. KATSILA, M. TOLIA, N. TSOUKALAS, M. LEONTSINIDIS, G. KYRGIAS, V. KOULOULIAS, G.P. PATRINOS, D. SPYROPOULOU, D. KARDAMAKIS (<i>Patras; Larisa; Athens, Greece</i>).....	1615
mTORC1 and mTORC2 Expression Levels in Oral Squamous Cell Carcinoma: An Immunohistochemical and Clinicopathological Study. G. KAWASAKI, T. NARUSE, K. FURUKAWA, M. UMEDA (<i>Nagasaki, Japan</i>).....	1623
Expression of Class III Beta-tubulin Predicts Prognosis in Patients with Cisplatin-resistant Bladder Cancer Receiving Paclitaxel-based Second-line Chemotherapy. Y. MIYATA, T. MATSUO, Y. NAKAMURA, T. YASUDA, K. OHBA, K. TAKEHARA, H. SAKAI (<i>Nagasaki, Japan</i>).....	1629
Associations Between Histogram Analysis DCE MRI Parameters and Complex ¹⁸ F-FDG-PET Values in Head and Neck Squamous Cell Carcinoma. A. SUROV, L. LEIFELS, H.J. MEYER, K. WINTER, O. SABRI, S. PURZ (<i>Leipzig, Germany</i>)	1637
Lenvatinib in Advanced Radioiodine-refractory Thyroid Cancer: A Snapshot of Real-life Clinical Practice. A. NERVO, M. GALLO, M.T. SAMÀ, F. FELICETTI, M. ALFANO, E. MIGLIORE, F. MARCHISIO, R. BERARDELLI, E. ARVAT, A. PIOVESAN (<i>Turin, Italy</i>).....	1643
National Practice Patterns for Clinical T1N0 Nasopharyngeal Cancer in the Elderly: A National Cancer Data Base Analysis. C.M. POST, C. LIN, S. ADEBERG, M. GUPTA, W. ZHEN, V. VERMA (<i>Omaha, NE; Kansas City, MO, USA; Heidelberg, Germany</i>)	1651
Upper Abdominal Resection for Isolated Metastatic Lesions in Recurrent Cervical Cancer. A. FILIPESCU, I. BALESCU, N. BACALBASA (<i>Bucharest, Romania</i>).....	1659
A Retrospective Multicenter Study of Carbon Ion Radiotherapy for Locally Advanced Olfactory Neuroblastomas. H. SUEFUJI, M. KOTO, Y. DEMIZU, J.-I. SAITOH, Y. SHIOYAMA, H. TSUJI, T. OKIMOTO, T. OHNO, K. NEMOTO, T. NAKANO, T. KAMADA (<i>Tosu; Chiba; Tatsuno; Maebashi; Yamagata, Japan</i>)	1665
Moderate Hypofractionation in Patients with Low-risk Prostate Cancer: Long-term Outcomes. M. VALERIANI, P. BONFILI, C. REVERBERI, L. MARINELLI, L. FERELLA, G. MINNITI, V. DE SANCTIS, M. FALCHETTO OSTI, P. BONOME, L. TRONNOLONE, E. VARRASSI, G.L. GRAVINA, P. FRANZESE, V. TOMBOLINI, M. DI STASO (<i>Rome; L'Aquila, Italy</i>).....	1671

COX2/PTGS2 Expression Is Predictive of Response to Neoadjuvant Celecoxib in <i>HER2</i> -negative Breast Cancer Patients. P. DE CREMOUX, A.-S. HAMY, J. LEHMANN-CHE, V. SCOTT, B. SIGAL, M.-C. MATHIEU, P. BERTHEAU, J.M. GUINEBRETIERE, J.Y. PIERGA, S. GIACCHETTI, E. BRAIN, M. MARTY, B. ASSELAIN, F. SPYRATOS, I. BIÈCHE (<i>Paris; Villejuif; Saint-Cloud, France</i>)	1485
Serum C-reactive Protein and Neutrophil/Lymphocyte Ratio After Neoadjuvant Radiotherapy in Soft Tissue Sarcoma. M. YANAGISAWA, A.A. GINGRICH, S. JUDGE, C.-S. LI, N. WANG, S.W. THORPE, A.R. KIRANE, R.J. BOLD, A.M. MONJAZEB, R.J. CANTER (<i>Sacramento; Davis, CA, USA</i>)	1491
Expression of Progesterone and Androgen Receptors in the Breast of Premenopausal Women, Considering Menstrual Phase. M. FAHLÉN, H. ZHANG, L. LÖFGREN, B. MASIRONI, E. VON SCHOULTZ, B. VON SCHOULTZ, L. SAHLIN (<i>Stockholm, Sweden</i>)	1499
Dose–function Histogram Evaluation Using ^{99m} Tc-GSA SPECT/CT Images for Stereotactic Body Radiation Therapy Planning for Hepatocellular Carcinoma Patients: A Dosimetric Parameter Comparison. R. TOYA, T. SAITO, S. SHIRAIISHI, Y. KAI, R. MURAKAMI, T. MATSUYAMA, T. WATAKABE, F. SAKAMOTO, N. TSUDA, Y. SHIMOHIGASHI, Y. YAMASHITA, N. OYA (<i>Kumamoto, Japan</i>)	1511
Transitory Stoma at the Time of Complete Cytoreductive Surgery Affects Survival for Patients with Advanced-stage Ovarian Cancer. G. CANLORBE, C. TOUBOUL, C. CHARGARI, E. BENTIVEGNA, A. MAULARD, P. PAUTIER, C. GENESTIE, P. MORICE, S. GOUY (<i>Villejuif, France</i>)	1517
Surveillance Imaging in HPV-related Oropharyngeal Cancer. W. SU, B.A. MILES, M. POSNER, P. SOM, L. KOSTAKOGLU, V. GUPTA, R.L. BAKST (<i>New York, NY, USA</i>)	1525
Synthesis and Binding of a Novel PSMA-specific Conjugate. A.R. HOLMBERG, M. MARQUEZ, L. LENNARTSSON, L. MEURLING, S. NILSSON (<i>Stockholm, Sweden</i>)	1531
Characterization and Management of Borderline Ovarian Tumors – Results of a Retrospective, Single-center Study of Patients Treated at the Department of Gynecology and Obstetrics of the University Medicine Greifswald. D. KOENSGEN, M. WEISS, K. ASSMANN, S.Y. BRUCKER, D. WALLWIENER, M.B. STOPE, A. MUSTEA (<i>Greifswald; Tuebingen, Germany</i>)	1539
Functionality of the Tumor Suppressor <i>microRNA-1</i> in Malignant Tissue and Cell Line Cells of Uterine Leiomyosarcoma. M.B. STOPE, V. CERNAT, A. KAUL, K. DIESING, D. KOENSGEN, M. BURCHARDT, A. MUSTEA (<i>Greifswald, Germany</i>)	1547
The Prognostic Significance of Hsp70/Hsp90 Expression in Breast Cancer: A Systematic Review and Meta-analysis. D.T. DIMAS, C.D. PERLEPE, T.N. SERGENTANIS, I. MISITZIS, K. KONTZOGLOU, E. PATSOURIS, G. KOURAKLIS, T. PSALTOPOULOU, A. NONNI (<i>Athens, Greece</i>)	1551
A Strategy for Using Intraoperative Nerve Monitoring During Esophagectomy to Prevent Recurrent Laryngeal Nerve Palsy. M. YUDA, K. NISHIKAWA, K. TAKAHASHI, T. KUROGOCHI, Y. TANAKA, A. MATSUMOTO, Y. TANISHIMA, N. MITSUMORI, K. YANAGA (<i>Tokyo, Japan</i>)	1563
Number of Resected Lymph Nodes and Survival of Patients with Locally Advanced Esophageal Squamous Cell Carcinoma Receiving Preoperative Chemoradiotherapy. J.-C. GUO, C.-C. LIN, T.-C. HUANG, P.-M. HUANG, H.-Y. KUO, C.-H. CHANG, C.-C. WANG, J.C.-H. CHENG, K.-H. YEH, C.-H. HSU, J.-M. LEE (<i>Taipei; Hsinchu, Taiwan, ROC</i>)	1569
Impact of Visceral Metastasis on Efficacy of Fulvestrant in Patients with Hormone Receptor-positive Recurrent Breast Cancer. Y. KOI, C. KOGA, S. AKIYOSHI, T. MASUDA, H. IJICHI, Y. NAKAMURA, M. ISHIDA, S. OHNO, E. TOKUNAGA (<i>Hiroshima; Fukuoka; Tokyo, Japan</i>)	1579

Suppressive Effect of Delta-Tocotrienol on Hypoxia Adaptation of Prostate Cancer Stem-like Cells. S. KANEKO, C. SATO, N. SHIOZAWA, A. SATO, H. SATO, N. VIRGONA, T. YANO (<i>Gunma; Chiba, Japan</i>)	1391
Reduced Tumour Proportion Scores for Programmed Cell Death Ligand 1 in Stored Paraffin Tissue Sections. Y. SATO, D. FUJIMOTO, K. UEHARA, H. KAWACHI, K. NAGATA, A. NAKAGAWA, K. OTSUKA, I. SAKANOUÉ, H. HAMAKAWA, Y. TAKAHASHI, Y. IMAI, K. TOMII (<i>Kobe, Japan</i>)	1401
Vitamins C and K3: A Powerful Redox System for Sensitizing Leukemia Lymphocytes to Everolimus and Barasertib. D. IVANOVA, Z. ZHELEV, D. LAZAROVA, P. GETSOV, R. BAKALOVA, I. AOKI (<i>Stara Zagora; Sofia, Bulgaria; Chiba, Japan</i>)	1407
The Comparison Between Molecular Tumour Profiling in Microdissected and Surgical Tissue Samples. I. LACZMANSKA, M. SASIADEK, L. LACZMANSKI (<i>Wroclaw, Poland</i>)	1415
Clinicopathological and Prognostic Significance of Epithelial Gremlin1 Expression in Gastric Cancer. R. HONMA, N. SAKAMOTO, A. ISHIKAWA, D. TANIYAMA, K. FUKADA, T. HATTORI, K. SENTANI, N. OUE, K. TANABE, H. OHDAN, W. YASUI (<i>Hiroshima, Japan</i>)	1419
Pre-exposure to Fluorouracil Increased Trifluridine Incorporation and Enhanced its Anti-tumor Effect for Colorectal Cancer. T. BABA, T. KOKURYO, J. YAMAGUCHI, Y. YOKOYAMA, K. UEHARA, T. EBATA, M. NAGINO (<i>Nagoya, Japan</i>)	1427
Clinical Implications of CD4 ⁺ CD25 ⁺ Foxp3 ⁺ Regulatory T Cell Frequencies After CHP-MAGE-A4 Cancer Vaccination. M. WADA, T. TSUCHIKAWA, N. KYOGOKU, T. ABIKO, K. MIYAUCHI, S. TAKEUCHI, T. KUWATANI, T. SHICHINOHE, Y. MIYAHARA, S. KAGEYAMA, H. IKEDA, H. SHIKU, S. HIRANO (<i>Sapporo; Mie; Nagasaki, Japan</i>)	1435
AZD8055 Exerts Antitumor Effects on Colon Cancer Cells by Inhibiting mTOR and Cell-cycle Progression. Y. CHEN, C.-H. LEE, B.-Y. TSENG, Y.-H. TSAI, H.-W. TSAI, C.-L. YAO, S.-H. TSENG (<i>New Taipei; Taoyuan; Hualien; Taipei, Taiwan, ROC</i>)	1445
Polymorphisms of <i>ABCB1</i> , <i>CYP3A4</i> and <i>CYP3A5</i> Genes in Ovarian Cancer and Treatment Response in Poles. Ł. FISZER-MALISZEWSKA, Ł. ŁACZMAŃSKI, A. DOLIŃSKA, M. JAGAS, E. KOŁODZIEJSKA, M. JANKOWSKA, P. KUŚNIERCZYK (<i>Wroclaw, Poland</i>)	1455
Curcumin and Rutin Down-regulate Cyclooxygenase-2 and Reduce Tumor-associated Inflammation in HPV16-Transgenic Mice. M.S.S. MOUTINHO, S. ARAGÃO, D. CARMO, F. CASACA, S. SILVA, J. RIBEIRO, H. SOUSA, I. PIRES, F. QUEIROGA, B. COLAÇO, R. MEDEIROS, P.A. OLIVEIRA, C. LOPES, M.M.S.M. BASTOS, R.M. GIL DA COSTA (<i>Vila Real; Porto, Portugal</i>)	1461
<i>Clinical Studies</i>	
Combined Oocyte Retrieval and Robot-assisted Hysterectomy in a Super Morbidly Obese Patient with Endometrial Carcinoma. E.H. CHUNG, P.C. BRADY, K.K. SMITH, M.R. DAVIS, M.G. MUTO, R.K. ASHBY, E.S. GINSBURG (<i>Boston, MA, USA</i>)	1467
A Panel of Biomarkers for Diagnosis of Prostate Cancer Using Urine Samples. J. GUO, J. YANG, X. ZHANG, X. FENG, H. ZHANG, L. CHEN, H. JOHNSON, J.L. PERSSON, K. XIAO (<i>Shenzhen; Beijing; Guangzhou, PR China; Sunnyvale, CA, USA; Malmö; Umeå, Sweden</i>)	1471
Clear Cell Sarcoma-like Tumor of the Gastrointestinal Tract: Clinical Outcome and Pathologic Features of a Molecularly Characterized Tertiary Center Case Series. M. LIBERTINI, K. THWAY, J. NOUJAIM, F. PULS, C. MESSIOU, C. FISHER, R.L. JONES (<i>London, UK; Montreal, Canada; Gothenburg, Sweden</i>)	1479

Update on Surgical Management of Small Bowel Neuroendocrine Tumors. D. MORIS, I. NTANASIS-STATHOPOULOS, D.I. TSILIMIGRAS, S. VAGIOS, A. KARAMITROS, G. KARAOLANIS, J. GRINIATSOS, A. PAPALAMPROS, I. PAPACONSTANTINOY, G.K. GLANTZOUNIS, E. SPARTALIS, D.G. BLAZER 3rd, E. FELEKOURAS (<i>Durham, NC, USA; Athens; Ioannina, Greece</i>)	1267
--	------

Experimental Studies

Detection of Distinct Changes in Gene-expression Profiles in Specimens of Tumors and Transition Zones of Tenascin-positive/-negative Head and Neck Squamous Cell Carcinoma. V. ZIVICOVA, P. GAL, A. MIFKOVA, S. NOVAK, H. KALTNER, M. KOLAR, H. STRNAD, J. SACHOVA, M. HRADILOVA, M. CHOVANEC, H.-J. GABIUS, K. SMETANA JR, Z. FIK (<i>Prague; Vestec, Czech Republic; Kosice, Slovak Republic; Munich, Germany</i>)	1279
--	------

Modulation of Tumor Cell Metabolism by Laser Photochemotherapy with Cisplatin or Zoledronic Acid <i>In Vitro</i> . P.G.B. HEYMANN, K.S.E. HENKENIUS, T. ZIEBART, A. BRAUN, K. HIRTHAMMER, F. HALLING, A. NEFF, R. MANDIC (<i>Marburg; Fulda, Germany</i>)	1291
---	------

Combination Treatment of Polo-Like Kinase 1 and Tankyrase-1 Inhibitors Enhances Anticancer Effect in Triple-negative Breast Cancer Cells. G.-H. HA, D.-Y. KIM, E.-K. BREUER, C.K. KIM (<i>Suwon, Republic of Korea; Maywood, IL, USA</i>)	1303
---	------

Chemotherapeutic Effect of CD147 Antibody-labeled Micelles Encapsulating Doxorubicin Conjugate Targeting CD147-Expressing Carcinoma Cells. T. ASAKURA, M. YOKOYAMA, K. SHIRAISHI, K. AOKI, K. OHKAWA (<i>Tokyo, Japan</i>)	1311
--	------

Mutational and Functional Analysis of <i>FANCB</i> as a Candidate Gene for Sporadic Head and Neck Squamous Cell Carcinomas. M.F. GLAAS, C. WIEK, L.-M. WOLTER, K. ROELLECKE, V. BALZ, V. OKPANYI, M. WAGENMANN, T.K. HOFFMANN, R. GRÄSSLIN, C. PLETTENBERG, J. SCHIPPER, H. HANENBERG, K. SCHECKENBACH (<i>Duesseldorf; Ulm; Essen, Germany</i>)	1317
--	------

Glucans and Cancer: Comparison of Commercially Available β -glucans – Part IV. V. VETVICKA, J. VETVICKOVA (<i>Louisville, KY, USA</i>)	1327
--	------

BRAF Inhibitors and Radiation Do Not Act Synergistically to Inhibit WT and V600E BRAF Human Melanoma. L. WALTER, L. HEINZERLING (<i>Erlangen, Germany</i>)	1335
--	------

Squamous Cell Carcinoma Antigen-encoding Genes <i>SERPINB3/B4</i> as Potentially Useful Markers for the Stratification of HNSCC Tumours. Z. SAIDAK, M.C. MORISSE, D. CHATELAIN, C. SAUZAY, A. HOUESSINON, N. GUILAIN, M. SOYEZ, B. CHAUFFERT, S. DAKPÉ, A. GALMICHE (<i>Amiens, France</i>)	1343
--	------

Inhibition of Asparagine-linked Glycosylation Participates in Hypoxia-induced Down-regulation of Cell-surface MICA Expression. N. YAMADA, N. KATO-KOGOE, K. YAMANEGI, H. NISHIURA, Y. FUJIHARA, S. FUKUNISHI, H. OKAMURA, N. TERADA, K. NAKASHO (<i>Nishinomiya; Takatsuki, Japan</i>)	1353
--	------

Expression of Sphingosine Kinase-1 Is Associated with Invasiveness and Poor Prognosis of Oral Squamous Cell Carcinoma. K. KATO, M. SHIMASAKI, T. KATO, N. SEGAMI, Y. UEDA (<i>Ishikawa, Japan</i>)	1361
--	------

Impact of Methadone on Cisplatin Treatment of Bladder Cancer Cells. M. MICHALSKA, S. SCHULTZE-SEEMANN, I. KUCKUCK, A. KATZENWADEL, P. WOLF (<i>Freiburg, Germany</i>)	1369
---	------

Galangin Induces p53-independent S-phase Arrest and Apoptosis in Human Nasopharyngeal Carcinoma Cells Through Inhibiting PI3K–AKT Signaling Pathway. C.-C. LEE, M.-L. LIN, M. MENG, S.-S. CHEN (<i>Taichung, Taiwan, ROC</i>)	1377
---	------